Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer
Li A, Goodyear S, Fuss C, Mitri Z. Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer. JCO Precision Oncology 2021, 5: 904-909. PMID: 34994619, DOI: 10.1200/po.20.00361.Peer-Reviewed Original Research